MA51075A - Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine - Google Patents
Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatineInfo
- Publication number
- MA51075A MA51075A MA051075A MA51075A MA51075A MA 51075 A MA51075 A MA 51075A MA 051075 A MA051075 A MA 051075A MA 51075 A MA51075 A MA 51075A MA 51075 A MA51075 A MA 51075A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- treating disorders
- follistatin polypeptides
- follistatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462007908P | 2014-06-04 | 2014-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51075A true MA51075A (fr) | 2020-10-14 |
Family
ID=54767384
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051074A MA51074A (fr) | 2014-06-04 | 2015-06-04 | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine |
MA051075A MA51075A (fr) | 2014-06-04 | 2015-06-04 | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051074A MA51074A (fr) | 2014-06-04 | 2015-06-04 | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine |
Country Status (12)
Country | Link |
---|---|
US (2) | US10023621B2 (fr) |
EP (2) | EP3721892B1 (fr) |
JP (3) | JP6568110B2 (fr) |
KR (4) | KR20210119546A (fr) |
CN (2) | CN106795224B (fr) |
AU (2) | AU2015269333B2 (fr) |
BR (1) | BR112016028520A2 (fr) |
CA (1) | CA2950754C (fr) |
EA (2) | EA202090632A1 (fr) |
MA (2) | MA51074A (fr) |
MX (2) | MX382908B (fr) |
WO (1) | WO2015187977A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201509620SA (en) | 2005-11-23 | 2015-12-30 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for promoting bone growth |
EP3415161A1 (fr) | 2008-06-26 | 2018-12-19 | Acceleron Pharma Inc. | Utilisation d'un antagoniste actriib pour le traitement de l'anémie |
EA201590719A1 (ru) | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
EA202090632A1 (ru) * | 2014-06-04 | 2020-07-31 | Акселерон Фарма Инк. | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов |
BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
CA2980757A1 (fr) * | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Proteines de fusion associees a la follistatine et leurs utilisations |
KR20180137487A (ko) * | 2016-03-04 | 2018-12-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도 |
US10905766B2 (en) | 2017-03-23 | 2021-02-02 | Oregon State University | Therapeutic compositions and methods for treatment of muscle wasting diseases |
KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
WO2019046903A1 (fr) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | Procédé thérapeutique pour augmenter la masse musculaire chez un sujet |
CN108218985B (zh) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用 |
EP3765601A1 (fr) * | 2018-03-16 | 2021-01-20 | Immusoft Corporation | Lymphocytes b génétiquement modifiées pour sécréter de la follistatine et leurs méthodes d'utilisation pour traiter des maladies, des états, des troubles liés à la follistatine et pour améliorer la croissance et la résistance musculaires |
JP7183291B2 (ja) * | 2018-03-21 | 2022-12-05 | 松陽生技股▲分▼有限公司 | 局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止する組成物及び当該組成物を使用して製造された薬物 |
WO2019191204A1 (fr) * | 2018-03-28 | 2019-10-03 | Acceleron Pharma Inc. | Polypeptides de follistatine pour le traitement de la contracture musculaire |
US20210207135A1 (en) * | 2018-05-17 | 2021-07-08 | Housey Pharmaceutical Research Laboratories, L.L.C. | Inhibition of follistatin |
WO2020046466A1 (fr) * | 2018-08-29 | 2020-03-05 | Myos Rens Technology, Inc. | Méthodes pour atténuer, inhiber ou inverser une atrophie musculaire par inaction chez le mammifère |
AU2023291634A1 (en) | 2022-06-15 | 2025-01-30 | UCB Biopharma SRL | Follistatin-fc fusion proteins |
IL317374A (en) | 2022-06-15 | 2025-02-01 | UCB Biopharma SRL | Fusion protein for the prevention, treatment or alleviation of kidney disease |
WO2024121351A1 (fr) * | 2022-12-07 | 2024-06-13 | Lodberg Andreas | Composés de liaison à une matrice extracellulaire pour le chargement localisé d'agents thérapeutiques ou diagnostiques |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US5182375A (en) | 1987-08-28 | 1993-01-26 | The Salk Institute For Biological Studies | DNA encoding follistatin |
US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
AU660662B2 (en) * | 1991-02-08 | 1995-07-06 | Progenics Pharmaceuticals, Inc. | CD4-gamma2 and CD4-IgG2 chimeras |
JPH08501314A (ja) | 1992-09-16 | 1996-02-13 | ジェネンテク,インコーポレイテッド | Hgfによる肝臓障害に対する保護 |
US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
EP0726948B1 (fr) | 1993-10-14 | 2007-02-28 | President And Fellows Of Harvard College | Procede d'induction et de maintien de cellules neuronales |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
WO1999006559A1 (fr) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Procedes d'identification des recepteurs des facteurs de differenciation de la croissance |
US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
AU777783B2 (en) | 1999-04-19 | 2004-10-28 | Kyowa Hakko Kogyo Co. Ltd. | Proliferation inhibitor for androgen-independent tumor |
WO2001009368A1 (fr) | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Antagonistes de la follistatine |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
CA2476654A1 (fr) | 2002-02-21 | 2003-09-04 | Wyeth | Domaine follistatine contenant des proteines |
WO2003072715A2 (fr) | 2002-02-21 | 2003-09-04 | Wyeth | Proteine contenant un domaine de follistatine |
CN1993048A (zh) * | 2002-02-21 | 2007-07-04 | 惠氏公司 | 包含促滤泡素抑制素结构域的蛋白质 |
WO2004082710A1 (fr) | 2003-03-21 | 2004-09-30 | Lorantis Limited | Traitement de maladies allergiques utilisant un modulateur de la voie de signalisation notch |
CN1829532A (zh) | 2003-06-02 | 2006-09-06 | 惠氏公司 | 肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途 |
US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
WO2005033134A2 (fr) * | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Therapeutique et utilisations d'une proteine secretee |
US8920806B2 (en) | 2003-10-06 | 2014-12-30 | Paranta Biosciences Limited | Method of modulating inflammatory response by downregulation of activin |
JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
AU2005266875B2 (en) * | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
AU2006283725B2 (en) | 2005-08-19 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
AU2006321906C1 (en) * | 2005-12-06 | 2014-01-16 | Amgen Inc. | Uses of myostatin antagonists |
WO2008030367A2 (fr) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Inhibiteurs sélectifs de la myostatine |
ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
JP5415279B2 (ja) | 2006-12-18 | 2014-02-12 | アクセルロン ファーマ, インコーポレイテッド | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
EP3415161A1 (fr) | 2008-06-26 | 2018-12-19 | Acceleron Pharma Inc. | Utilisation d'un antagoniste actriib pour le traitement de l'anémie |
EP2318028B1 (fr) * | 2008-06-26 | 2020-02-19 | Acceleron Pharma Inc. | Antagonistes solubles d'activine-actriia et utilisations pour augmenter les taux d'érythrocytes |
KR20200086378A (ko) * | 2009-09-09 | 2020-07-16 | 악셀레론 파마 인코포레이티드 | ActRIIb 길항제들와 이의 투약 및 용도 |
JP5813114B2 (ja) * | 2010-08-25 | 2015-11-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Il−18r1に対する抗体およびその使用 |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
CA2867202A1 (fr) | 2012-05-17 | 2013-11-21 | Paranta Biosciences Limited | Procede de traitement et agents utiles pour celui-ci |
WO2014003553A1 (fr) * | 2012-06-27 | 2014-01-03 | Arthrogen B.V. | Combinaison de traitement d'un trouble inflammatoire |
EA201590719A1 (ru) * | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
WO2014187807A1 (fr) * | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Dérivés de follistatine |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
EA202090632A1 (ru) * | 2014-06-04 | 2020-07-31 | Акселерон Фарма Инк. | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов |
CA2980757A1 (fr) * | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Proteines de fusion associees a la follistatine et leurs utilisations |
MX2019013523A (es) | 2017-05-12 | 2020-07-14 | Takeda Pharmaceuticals Co | Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne. |
-
2015
- 2015-06-04 EA EA202090632A patent/EA202090632A1/ru unknown
- 2015-06-04 MA MA051074A patent/MA51074A/fr unknown
- 2015-06-04 KR KR1020217029755A patent/KR20210119546A/ko not_active Ceased
- 2015-06-04 AU AU2015269333A patent/AU2015269333B2/en not_active Ceased
- 2015-06-04 KR KR1020207003791A patent/KR102132144B1/ko active Active
- 2015-06-04 CA CA2950754A patent/CA2950754C/fr active Active
- 2015-06-04 US US14/731,009 patent/US10023621B2/en active Active
- 2015-06-04 EP EP20160287.7A patent/EP3721892B1/fr active Active
- 2015-06-04 MA MA051075A patent/MA51075A/fr unknown
- 2015-06-04 CN CN201580041740.2A patent/CN106795224B/zh active Active
- 2015-06-04 KR KR1020177000297A patent/KR102077286B1/ko not_active Expired - Fee Related
- 2015-06-04 EP EP15802909.0A patent/EP3152237B1/fr active Active
- 2015-06-04 WO PCT/US2015/034245 patent/WO2015187977A1/fr active Application Filing
- 2015-06-04 MX MX2016015868A patent/MX382908B/es unknown
- 2015-06-04 BR BR112016028520A patent/BR112016028520A2/pt not_active Application Discontinuation
- 2015-06-04 CN CN202110533308.2A patent/CN113583104A/zh active Pending
- 2015-06-04 KR KR1020207018965A patent/KR102305109B1/ko active Active
- 2015-06-04 JP JP2016570806A patent/JP6568110B2/ja active Active
- 2015-06-04 EA EA201692529A patent/EA035455B1/ru not_active IP Right Cessation
-
2016
- 2016-12-01 MX MX2021006017A patent/MX2021006017A/es unknown
-
2018
- 2018-06-12 US US16/006,025 patent/US10954279B2/en active Active
-
2019
- 2019-08-01 JP JP2019142333A patent/JP6856716B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-03 AU AU2020210315A patent/AU2020210315A1/en not_active Abandoned
-
2021
- 2021-03-18 JP JP2021044545A patent/JP2021095416A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51075A (fr) | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine | |
IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
EP3364993A4 (fr) | Procédés pour traiter le syndrome d'angelman et des troubles associés | |
SMT202000414T1 (it) | Composizioni e metodi per trattare disturbi del snc | |
SMT202000276T1 (it) | Composizioni e metodi per trattare disturbi del snc | |
EP3319976A4 (fr) | Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires | |
SI3250210T1 (sl) | Sestavki in metode za zdravljenje CNS motenj | |
EP3353278A4 (fr) | Préparation d'échantillons pour des types d'échantillons compliqués | |
EP3390642A4 (fr) | Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13 | |
MA44886A (fr) | Compositions et méthode pour traiter des troubles acide-base | |
EP3180022A4 (fr) | Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase | |
EP3703706A4 (fr) | Compositions et méthode pour traiter des troubles acide-base | |
EP3291693A4 (fr) | Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques | |
GB201411241D0 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
EP3358929A4 (fr) | Procédés et appareils pour le traitement d'une matière agricole | |
GB201401086D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
EP3204028A4 (fr) | Composition synergique pour l'arthrose | |
EP3551162C0 (fr) | Composition appropriée pour le nettoyage | |
FR3020758B1 (fr) | Composition pour ameliorer l'hygiene buco-dentaire | |
MA44747A (fr) | Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique | |
EP3377073A4 (fr) | Méthodes et compositions pour traiter des troubles et des maladies à l'aide de la protéine de survie des motoneurones (smn) | |
EP3294339A4 (fr) | Méthodes et compositions pour le traitement de l'arthrite | |
EP3328428A4 (fr) | Procédés et compositions pour le traitement de maladies et de troubles immunomodulateurs | |
FR3040122B1 (fr) | Casier formant nasse pour des mollusques | |
EP3436021A4 (fr) | Compositions et méthodes pour traiter des troubles du déficit de l'attention |